APEIRON Biologics AG

42 articles about APEIRON Biologics AG

• Apeiron Announces Publication of Clinical Data With Anti-GD2 Antibody Demonstrating Efficacy in Relapsed & Refractory High-Risk Neuroblastoma

  12/18/2017

  The study successfully explored a GD2 antibody administration schedule of 10 day continuous slow infusion, to limit treatment-associated neuropathic pain, while preserving efficacy.

• Marketing Approval For Children’s Cancer Immunotherapy In The EU: Outstanding Success For Privately Financed Austrian Biotech Company APEIRON

  5/10/2017

• EUSA Pharma And APEIRON Receive Positive CHMP Opinion For Dinutuximab Beta For The Treatment Of High-Risk Neuroblastoma In Europe

  3/27/2017

• APEIRON And Columbia University Have Entered Into An Exclusive License Agreement That Expands Apeiron's Immune Checkpoint Blockade IP Portfolio

  2/16/2016

• APEIRON Biologics AG Collaborates With Idis Ltd to Initiate Managed Access Program

  9/25/2013

• Rentschler Biotechnologie GmbH & Co. Produces APEIRON Biologics AG's Monoclonal Antibody APN311 for Late Stage Clinical Development and Market

  8/1/2013

• APEIRON Biologics AG Release: Success in Avoiding Radiation Skin Damage for Breast Cancer Patients

  3/5/2013

• APEIRON Biologics AG Closes Regional License Agreement for Antibody-Based Immunotherapy

  1/18/2013

• APEIRON Biologics AG Establishes Biotech-Spinoff Attoquant Diagnostics

  12/4/2012

• APEIRON Biologics AG Initiates Clinical Study to Investigate Prevention of Radiation-Induced Skin Damage in Breast Cancer Patients

  2/27/2012

• APEIRON Biologics AG Release: Start of Phase IIa Study in Acute Lung Injury Patients Marks Development Milestone

  12/19/2011

• Evotec AG and APEIRON Biologics AG Start Next Project on the Cbl-b Target

  10/20/2011

• Children's Oncology Group and APEIRON Biologics AG to Jointly Conduct Phase II Study in Neuroblastoma With hu14.18-IL2 (APN301)

  9/29/2011

• Oncology Alliance: APEIRON Biologics AG, CCRI and SIOGEN Biotech Join Forces Against Neuroblastoma

  6/21/2011

• Apeiron Biologics Acquires Option to License Rights to Novel Oncology Compounds from Cleveland Clinic

  3/15/2011

• Experienced Venture Capitalist/Pharma Manager Joins Apeiron Biologics' Business Development Team

  1/10/2011

• Apeiron Biologics Acquires Rights to New Clinical Stage Project

  11/4/2010

• Evotec Technologies GmbH and Apeiron Biologics Build Pain Alliance

  10/27/2010

• Apeiron Biologics Nominated for the Most Important European Biotechnology Award

  8/19/2010

• Finalists For the EUROPEAN BIOTECHNICA AWARD 2010 Named

  8/13/2010